■血液恶性肿瘤(HM)是众所周知的坏疽性脓皮病(PG)的潜在合并症。然而,量化HMs后PG可能性的研究尚未进行。
■为了研究PG和几个HM之间的双向关联,即急性白血病,慢性白血病,霍奇金淋巴瘤,非霍奇金淋巴瘤,和多发性骨髓瘤.
■进行了一项基于人群的回顾性队列研究,以研究PG(n=302)患者的HMs风险与年龄,性别和种族匹配的对照受试者(n=1,799)。使用病例对照设计来估计先前有HMs病史的个体中PG的可能性。通过Cox回归和逻辑回归来估计调整后的风险比(HRs)和调整后的比值比(ORs)。分别。
■PG患者先前存在的HM的患病率高于对照组(6.7%vs.0.9%,分别)。在有HM病史的患者中,患PG的可能性明显更大(调整后的OR,7.88;95%CI,3.85-16.15;p<0.001),特别是在诊断后的第一年。这种关联对急性白血病很重要,慢性白血病,非霍奇金淋巴瘤,和多发性骨髓瘤,但不是霍奇金淋巴瘤。在PG患者和对照组中,HM的发生率为3.3(95%CI,1.2-7.4)和1.6(95%CI,0.9-2.6)/1,000人年,分别。相对于控件,PG患者不太可能发生后续HM(调整后的HR,2.22;95CI,0.77-6.45;p=0.142)。与其他PG患者相比,患有HM相关PG的患者全因死亡率增加(调整后的HR,2.19;95CI,1.09-4.40;p=0.028)。
■HM,特别是急性白血病和多发性骨髓瘤,与引发PG的可能性增加有关。
UNASSIGNED: Hematologic malignancies (HMs) are well-known underlying comorbidities of pyoderma gangrenosum (PG). However, studies quantifying the likelihood of PG after HMs are yet to be performed.
UNASSIGNED: To investigate the bidirectional association between PG and several HMs, namely acute leukemia, chronic leukemia, Hodgkin lymphoma, non-Hodgkin lymphoma, and multiple myeloma.
UNASSIGNED: A population-based retrospective cohort study was conducted to study the risk of HMs in patients with PG (n = 302) as compared to age-, sex-and ethnicity-matched control subjects (n = 1,799). A case-control design was used to estimate the likelihood of PG in individuals with a preexisting history of HMs. Adjusted hazard ratios (HRs) and adjusted odds ratios (ORs) were estimated by Cox regression and logistic regression, respectively.
UNASSIGNED: The prevalence of preexisting HM was higher in patients with PG than in controls (6.7% vs. 0.9%, respectively). The likelihood of having PG was significantly greater among patients with a history of HM (adjusted OR, 7.88; 95% CI, 3.85-16.15; p < 0.001), particularly during the first year following the diagnosis. This association was significant for acute leukemia, chronic leukemia, non-Hodgkin lymphoma, and multiple myeloma but not for Hodgkin lymphoma. The incidence rate of HM was 3.3 (95% CI, 1.2-7.4) and 1.6 (95% CI, 0.9-2.6)/1,000 person-years among patients with PG and controls, respectively. Relative to controls, patients with PG were not more likely to develop subsequent HM (adjusted HR, 2.22; 95%CI, 0.77-6.45; p = 0.142). Compared to other patients with PG, those with HM-associated PG experienced an increased all-cause mortality rate (adjusted HR, 2.19; 95%CI, 1.09-4.40; p = 0.028).
UNASSIGNED: HM, particularly acute leukemia and multiple myeloma, are associated with an elevated likelihood of provoking PG.